loading page

Putative Phospholipase B-like 2 (PLBD2) is not responsible for polysorbate degradation in monoclonal antibody drug products
  • +3
  • sisi Zhang,
  • hui xiao,
  • michael Goren,
  • Darya Burakov,
  • Gang chen,
  • Ning Li
sisi Zhang
Regeneron Pharmaceuticals Inc
Author Profile
hui xiao
Regeneron Pharmaceuticals Inc
Author Profile
michael Goren
Regeneron Pharmaceuticals Inc
Author Profile
Darya Burakov
Regeneron Pharmaceuticals Inc
Author Profile
Gang chen
Regeneron Pharmaceuticals Inc
Author Profile
Ning Li
Regeneron Pharmaceuticals Inc
Author Profile

Abstract

Polysorbates (PS) are surfactants commonly added in a therapeutic protein drug product as excipients to protect proteins from denaturation and aggregation during storage, transportation, and delivery. Significant degradation of PS in drug products could lead to shortened drug shelf lives and PS-degrading activity in drug products must be minimized. Identification of lipases that degrade PS could lead to better process control in drug manufacturing. In 2016, phospholipase B-like 2 (PLBD2) was proposed as a residual host cell protein responsible for degrading PS20 in a drug formulation. We have carried out a series of studies to verify the role of PLBD2 in degrading polysorbates in drug products purified from recombinant Chinese Hamster Ovary (CHO) cells. Genetic knock-out and immuno-depletion results showed that when PLBD2 was removed or depleted, the degradation of PS20 or PS80 was neither diminished nor reduced. In addition, a quantitative analysis of PLBD2 and PS20 degradation in multiple formulated mAb products did not establish a correlation between the amount of PLBD2 and the level of PS20 degradation. Collectively these results suggest that PLBD2 is not the primary cause of polysorbate degradation in formulated drug products purified using standard Protein A and ion exchange chromatography.